Side-by-Side Comparison FDA Approved Tesamorelin Yes (Egrifta, 2010) CJC-1295/Ipamorelin No (compounded) Tesamorelin/Ipamorelin No (compounded combo) Mechanism Tesamorelin GHRH receptor (single pathway) CJC-1295/Ipamorelin GHRH + ghrelin receptor (dual pathway) Tesamorelin/Ipamorelin GHRH + ghrelin (FDA molecule + dual pathway) Half-Life Extension Tesamorelin DPP-IV protection (~26 min) CJC-1295/Ipamorelin Enzyme-resistant substitutions (~30 min, no-DAC) Tesamorelin/Ipamorelin DPP-IV protection + ghrelin receptor Clinical Evidence Tesamorelin 2 Phase 3 RCTs, 816 patients CJC-1295/Ipamorelin Phase 2 (CJC-1295) Tesamorelin/Ipamorelin Individual components well-studied Fat Loss Data Tesamorelin 15% visceral fat reduction (CT-measured) CJC-1295/Ipamorelin Body composition improvement (practitioner data) Tesamorelin/Ipamorelin Combined mechanisms Liver Fat Tesamorelin 35% normalized liver fat (Lancet HIV, 2019) CJC-1295/Ipamorelin Not specifically studied Tesamorelin/Ipamorelin Tesamorelin component covers this Sleep Benefit Tesamorelin Moderate CJC-1295/Ipamorelin Strong (dual-pathway overnight GH) Tesamorelin/Ipamorelin Strong Regulatory Pedigree Tesamorelin Strongest (current FDA approval) CJC-1295/Ipamorelin Standard compounded Tesamorelin/Ipamorelin FDA molecule + compounded Tesamorelin: The FDA-Approved Option Tesamorelin has the strongest clinical evidence of any growth hormone peptide
The Summer Lab Social Impact Track, which debuted last year, will feature projects with 11th Hour organizations Inclusive Development International, mBio, Remora Fishing Traceability, the Schmidt Ocean Institute, and WoMin African Alliance, as well as local non-profit BPI Chicago
[DOI] [PubMed] [Google Scholar] 166.Alqarni M.H., Foudah A.I., Muharram M.M., Labrou N.E
In these trials, it selectively reduces visceral fat (not subcutaneous3/5) Sermorelin is similar to your bodys natural GHRH
